胃がんを予防するためのヘリコバクター・ピロリのスクリーニング: 実用的なランダム化臨床試験
Yi-Chia Lee1,2,3,4, Tsung-Hsien Chiang1,4,5, Han-Mo Chiu1,4
1Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.
JAMA
|September 30, 2024
まとめ
糞便免疫化学検査 (FIT) のヘリコバクター・パイロリ (H. pylori) のスクリーニングは,台湾で胃がんの発生率や死亡率を減少させなかった. しかし,調整された分析では,胃がんの発生率に対する潜在的な利益が示唆され,さらなる調査が必要となった.
科学分野:
- 胃腸内科
- 腫瘍学
- 予防医学
背景:
- ヘリコバクター・パイロリ (H. pylori) のスクリーニングが胃がんの発生率に与える影響は不明である.
- 胃がんは世界的な健康問題であり 効果的なスクリーニング戦略が必要です
研究 の 目的:
- 糞便免疫化学検査 (FIT) と並行して,Hパイロリ便抗原 (HPSA) 検査に誘うことが胃がんの発生率と死亡率に与える影響を評価する.
- 結合されたH・パイロリと結腸がんのスクリーニングアプローチの有効性を評価する.
主な方法:
- 台湾の50歳から69歳の住民を対象とした実用的なランダム化臨床試験.
- 参加者はランダムに HPSA + FIT または FIT 単独の招待を受けるように割り当てられました.
- 主なアウトカムには胃がんの発生率と死亡率が含まれ,フォローアップは2020年12月まで続いた.
主要な成果:
- HPSA + FITの誘導は,FIT単独と比較して,胃がんの発生率や死亡率を有意に低下させなかった.
- スクリーニング参加と追跡期間を調整したポストホック分析では,HPSA + FITグループにおける胃がん発生率 (死亡率ではない) が著しく減少したことを示した.
- 腹痛と消化不良を含む抗生物質治療による報告された副作用は,一般的に軽度でした.
結論:
- 胃がんの発生率や死亡率の有意な減少は示されなかった.
- 調整された分析は,胃がんの発生率を減らすためにHパイロリスクリーニングの潜在的な利点を示唆し,さらなる研究に値する.
- この結果は,スクリーニング介入の評価の複雑さと,参加バイアスの考慮の重要性を強調しています.
関連する概念動画
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
94
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
94
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
01:23Gastritis III: Clinical Manifestations and Management
172
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
172
01:12Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
57
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
57